Screener
Viridian Therapeutics, Inc. VRDN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s total equity?
- Viridian Therapeutics, Inc. (VRDN) reported total equity of $662.1M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s total equity changed year-over-year?
- Viridian Therapeutics, Inc.'s total equity increased by 28.5% year-over-year, from $515.17M to $662.1M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s total equity has grown at a 43.2% compound annual growth rate (CAGR), from $120.04M to $722.17M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Viridian Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude